Mucoadhesive suppositories of ramosetron hydrochloride utilizing Carbopol®

International Journal of Pharmaceutics

Volumn 193, Issue 2, 2000, Pages 205-212

  Yahagi, R ^a   Machida, Y ^a,b   Onishi, H ^a  

^a HOSHI UNIVERSITY   (Japan)

^b CANCER INSTITUTE HOSPITAL   (Japan)

Author keywords

Antiemetic; Carbopol ; Mucoadhesive suppository; Ramosetron; Serotonin receptor antagonist

Indexed keywords

CARBOMER; RAMOSETRON; WITEPSOL H 15;

ANIMAL EXPERIMENT; ANTIEMETIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG RELEASE; DRUG SAFETY; MALE; NAUSEA; NONHUMAN; PRIORITY JOURNAL; RABBIT; SUPPOSITORY; VISCOSITY; VOMITING;

ADHESIVENESS; ANIMALS; AREA UNDER CURVE; BENZIMIDAZOLES; DRUG CARRIERS; INTESTINAL MUCOSA; IRRITANTS; MALE; POLYVINYLS; RABBITS; RECTUM; SEROTONIN ANTAGONISTS; SUPPOSITORIES; VISCOSITY;

EID: 0033987026     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5173(99)00338-5     Document Type: Article

References (18)

1. Andrews P.L.R., Bhandari P. The 5-hydroxytryptamine receptor antagonists as antiemetics: preclinical evaluation and mechanism of action. Eur. J. Cancer. 29A(1):1993;11-16.
2. Andrews P.L.R., Davis C.J., Bingham S., Davidson H.I.M., Hawthorn J., Maskell L. The abdominal visceral innervation and the emetic reflex: pathways, pharmacology, and plasticity. Can. J. Physiol. Pharmacol. 68:1990;325-345.
3. De Boer A.G., Moolenaar F., De Leede L.G.J., Breimer D.D. Rectal drug administration: clinical pharmacokinetic considerations. Clin. Pharmacokinet. 7:1982;285-311.
4. 3 receptor antagonist, on cisplatin-induced emesis in ferrets. Clin. Rep. 28(8):1994;2337-2347.
5. Hsyu P-H., Pritchard J.F., Bozigian H.P., Lloyd T.L., Griffin R.H., Shamburek R., Krishna G., Barr W.H. Comparison of the pharmacokinetics of an ondansetron solution (8 mg) when administered intravenously, orally, to the colon, and to the rectum. Pharm. Res. 11(1):1994;156-159.
6. Iwamoto Y., Tabata H., Morimoto K., Morisaka K. Sustained-release characteristics and bioavailability of dicrofenac-Na suppository containing carbopol. J. Pharm. Sci. Technol. Jpn. 47(4):1987;244-247.
7. Iwata M., Machida Y., Nagai T., Masuda H. Double-layered stick-type formulation of bleomycin for treatment of uterine cervical cancer. Drug Des. Delivery. 1:1987;253-260.
8. Iwata M., Machida Y., Shirotake S., Takayama K., Nagai T. Newly developed release test method for suppository. Jpn. J. Hosp. Pharm. 21(1):1995;29-36.
9. Kelly J.W., He L., Stewart J.T. High-performance liquid chromatographic separation of ondansetron enantiomers in serum using a cellulose-derivatized stationary phase and solid-phase extraction. J. Chromatogr. 622:1993;291-295.
10. 3 receptor antagonist, ondansetron, from a suppository containing a tablet in rabbits. J. Pharm. Sci. Technol. Jpn. 56(2):1996;103-107.
11. Machida Y., Masuda H., Fujiyama N., Ito S., Iwata M., Nagai T. Preparation and phase II clinical examination of topical dosage form for treatment of carcinoma colli containing bleomycin with hydroxypropyl cellulose. Chem. Pharm. Bull. 27(1):1979;93-100.
12. Miura H., Takeshige T., Kobayashi S., Higuchi S. A simple method for the determination of YM060 in plasma and urine by high performance liquid chromatography. Biomed. Chromatogr. 8:1994;103-104.
13. Morimoto K., Hama I., Nakamoto Y., Takeeda T., Hirano E., Morisaka K. Pharmaceutical studies of polyacrylic acid aqueous gel bases: absorption of insulin from polyacrylic acid aqueous gel bases following rectal administration in alloxan diabetic rats and rabbits. J. Pharm. Dyn. 3:1980;24-32.
14. Morimoto K., Kamiya E., Takeeda T., Nakamoto Y., Morisaka K. Enhancement of rectal absorption of insulin in polyacrylic acid aqueous gel bases containing long chain fatty acid in rats. Int. J. Pharm. 14:1983;149-157.
15. Moriyama Y., Arimori K., Nakano M. Absorption characteristics of azasetron from rectal and oral routes in rabbits. Biol. Pharm. Bull. 20(6):1997;701-703.
16. 3-receptor antagonist, GR38032F. Cancer Treat. Rev. 14:1987;333-336.
17. Tortorice P.V., O'Connell M.B. Management of chemotherapy-induced nausea and vomiting. Pharmacotherapy. 10(2):1990;129-145.
18. Triozzi P.L., Laszlo J. Optimum management of nausea and vomiting in cancer chemotherapy. Drugs. 34:1987;136-149.